睿知中国疾病研究地图
候选清单0

即将招募多发性骨髓瘤早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07628595,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Diagnosis of multiple myeloma (MM) according to IMWG response criteria, with BCMA target antigen expression on MM cells confirmed by flow cytometry or bone marrow pathology and immunohistochemistry;

    入选标准第 3 条

  3. Received at least 2 prior lines of anti-multiple myeloma therapy, with each line containing at least one complete treatment cycle, and documented disease progression during or after the most recent anti-myeloma therapy based on assessment data;

    入选标准第 4 条

    Males and females of childbearing potential must agree to use effective contraception from the date of informed consent signing until 1 year after the end of study treatment;

    入选标准第 30 条

    Males and females of childbearing potential must agree not to donate gametes (including sperm or ova) from the date of informed consent signing until 1 year after the end of study treatment;

    入选标准第 31 条

    Received targeted therapy, epigenetic therapy, other investigational drug therapy, or treatment involving invasive investigational medical devices within 5 half-lives;

    排除标准第 3 条

    Received systemic immunologic or non-immunologic therapy within 1 week;

    排除标准第 4 条

    Received cytotoxic therapy within 1 week;

    排除标准第 5 条

    Received proteasome inhibitor and immunomodulatory therapy within 2 weeks;

    排除标准第 6 条

    Received allogeneic hematopoietic stem cell transplantation within 6 months prior to dosing, or autologous hematopoietic stem cell transplantation within 3 months prior to dosing;

    排除标准第 8 条

    Received surgery within 2 weeks prior to dosing, or planned surgery within 2 weeks after dosing (except for local anesthesia procedures);

    排除标准第 23 条

  4. ECOG performance status of 0-2, with an estimated life expectancy of ≥3 months;

    入选标准第 10 条

  5. Absolute neutrophil count (ANC) ≥ 600/μL (no granulocyte colony-stimulating factor [G-CSF] used within 1 week prior to screening, or no pegylated G-CSF used within 2 weeks prior to screening);

    入选标准第 13 条

    Platelet count ≥ 50,000/μL;

    入选标准第 14 条

    Normal renal function during screening or within 2 months prior to screening: creatinine clearance (CrCl) (calculated by the Cockcroft-Gault formula) ≥ 45 mL/min;

    入选标准第 17 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN);

    入选标准第 19 条

  6. Clinical relapse: a. New bone lesions or soft tissue plasmacytomas (excluding osteoporotic fractures); b. Definite increase in existing plasmacytomas or bone lesions (sum of the products of perpendicular diameters [SPD] of measurable lesions increased by ≥50% with an absolute increase of ≥1 cm);

    入选标准第 9 条

  7. History of malignancy other than multiple myeloma prior to screening, except for the following: malignancies treated with curative intent and with no known active disease for ≥2 years prior to enrollment; adequately treated non-melanoma skin cancer with no current evidence of disease;

    排除标准第 9 条

    Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), with peripheral blood hepatitis B virus (HBV) DNA titer above the normal range detected within 6 months prior to infusion; positive hepatitis C virus (HCV) antibody with peripheral blood HCV RNA titer above the normal range; positive human immunodeficiency virus (HIV) antibody; positive syphilis test;

    排除标准第 12 条

  8. For females of childbearing potential, a negative pregnancy test at screening and prior to dosing, and not currently breastfeeding;

    入选标准第 29 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07628595,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects must meet all of the following criteria to be enrolled in this study:
  2. Age ≥18 years, either sex;
  3. Diagnosis of multiple myeloma (MM) according to IMWG response criteria, with BCMA target antigen expression on MM cells confirmed by flow cytometry or bone marrow pathology and immunohistochemistry;
  4. Received at least 2 prior lines of anti-multiple myeloma therapy, with each line containing at least one complete treatment cycle, and documented disease progression during or after the most recent anti-myeloma therapy based on assessment data;
  5. Measurable disease at screening, defined as meeting at least one of the following criteria:
  6. Serum M-protein ≥ 0.5 g/dL;
  7. Urine M-protein level ≥ 200 mg/24 h;
  8. Involved serum free light chain ≥ 10 mg/dL with abnormal serum free light chain κ/λ ratio;
  9. Clinical relapse: a. New bone lesions or soft tissue plasmacytomas (excluding osteoporotic fractures); b. Definite increase in existing plasmacytomas or bone lesions (sum of the products of perpendicular diameters [SPD] of measurable lesions increased by ≥50% with an absolute increase of ≥1 cm);
  10. ECOG performance status of 0-2, with an estimated life expectancy of ≥3 months;
  11. Bone marrow function test results (at screening or within 2 months prior to screening) meeting the following conditions:
  12. Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week prior to screening), with recombinant human erythropoietin permitted; for patients meeting the hemoglobin ≥ 6 g/dL enrollment criterion, red blood cell transfusions may be allowed to maintain hemoglobin ≥ 6 g/dL;
  13. Absolute neutrophil count (ANC) ≥ 600/μL (no granulocyte colony-stimulating factor [G-CSF] used within 1 week prior to screening, or no pegylated G-CSF used within 2 weeks prior to screening);
  14. Platelet count ≥ 50,000/μL;
  15. Lymphocyte count ≥ 500/μL;
  16. Absolute CD3-positive T-cell count ≥ 150/μL;
  17. Normal renal function during screening or within 2 months prior to screening: creatinine clearance (CrCl) (calculated by the Cockcroft-Gault formula) ≥ 45 mL/min;
  18. Hepatic function during screening or within 2 months prior to screening meeting the following conditions:
  19. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN);
  20. Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia, such as Gilbert's syndrome, where direct bilirubin may be ≤ 1.5 × ULN);
  21. Albumin ≥ 3 g/dL;
  22. Cardiac function during screening or within 2 months prior to screening meeting the following conditions:
  23. Left ventricular ejection fraction (LVEF) ≥ 40% (assessed by echocardiography or MUGA scan);
  24. No clinically significant pericardial effusion;
  25. No clinically significant electrocardiogram abnormalities;
  26. Pulmonary function during screening or within 2 months prior to screening meeting the following conditions:
  27. Oxygen saturation ≥ 90%;
  28. No clinically significant pleural effusion;
  29. For females of childbearing potential, a negative pregnancy test at screening and prior to dosing, and not currently breastfeeding;
  30. Males and females of childbearing potential must agree to use effective contraception from the date of informed consent signing until 1 year after the end of study treatment;
  31. Males and females of childbearing potential must agree not to donate gametes (including sperm or ova) from the date of informed consent signing until 1 year after the end of study treatment;
  32. The subject or their legally authorized representative has signed the Informed Consent Form (ICF), indicating understanding of the study objectives and procedures, and voluntary participation in this study.

排除标准:Exclusion Criteria:

  1. Subjects meeting any of the following criteria will be excluded from the study:
  2. Received other anti-tumor therapy during the screening period (as determined primarily by the investigator):
  3. Received targeted therapy, epigenetic therapy, other investigational drug therapy, or treatment involving invasive investigational medical devices within 5 half-lives;
  4. Received systemic immunologic or non-immunologic therapy within 1 week;
  5. Received cytotoxic therapy within 1 week;
  6. Received proteasome inhibitor and immunomodulatory therapy within 2 weeks;
  7. Received radiotherapy within 4 weeks (except if the radiation field involves ≤5% of bone marrow reserve, in which case there is no restriction on the time since completion of radiotherapy, and the subject may still be enrolled);
  8. Received allogeneic hematopoietic stem cell transplantation within 6 months prior to dosing, or autologous hematopoietic stem cell transplantation within 3 months prior to dosing;
  9. History of malignancy other than multiple myeloma prior to screening, except for the following: malignancies treated with curative intent and with no known active disease for ≥2 years prior to enrollment; adequately treated non-melanoma skin cancer with no current evidence of disease;
  10. Previously received any therapy utilizing vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped virus;
  11. Presence of severe and uncontrolled infection during screening (including bacterial, viral, fungal, etc.);
  12. Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb), with peripheral blood hepatitis B virus (HBV) DNA titer above the normal range detected within 6 months prior to infusion; positive hepatitis C virus (HCV) antibody with peripheral blood HCV RNA titer above the normal range; positive human immunodeficiency virus (HIV) antibody; positive syphilis test;
  13. Symptomatic heart failure or other cardiac diseases, such as severe arrhythmias:
  14. New York Heart Association (NYHA) Class III or IV congestive heart failure;
  15. Myocardial infarction within 6 months prior to informed consent signing, or prior coronary artery bypass grafting (CABG) or coronary artery stent implantation;
  16. Clinically significant ventricular arrhythmias or history of unexplained syncope (excluding vasovagal or dehydration-induced syncope);
  17. History of severe non-ischemic cardiomyopathy;
  18. Other clinically significant diseases, including:
  19. Primary immunodeficiency;
  20. Stroke or seizure within 6 months prior to screening;
  21. Definite clinical evidence of dementia or altered mental status;
  22. Parkinson's disease, parkinsonian movement disorders, or relevant history;
  23. Received surgery within 2 weeks prior to dosing, or planned surgery within 2 weeks after dosing (except for local anesthesia procedures);
  24. Received live attenuated vaccines within 1 month prior to dosing;
  25. Known severe allergic reaction to RN9101 or any of its formulation components;
  26. Known severe allergic reaction to tocilizumab;
  27. Patients unsuitable for intravenous infusion;
  28. Other conditions deemed by the investigator as rendering the subject unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07628595, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07628595,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07628595